




Supplementary Information



Supplementary Figure S1: HSC-Ad secretes adipokines-Ad-CM was subject to individual ELISAs (R&D Systems). The indicated adipokines were confirmed and quantified.



Supplementary Figure S2: HGF and VEGF are dispensable for Ad-CM-supported tumor cell proliferation-Tumor cells were cultured for 3 days in (A) αMEM or 100 ng/mL of HGF or VEGF, and (B) Ad-CM or Ad-CM supplemented with 1 μg/mL of anti-HGF or anti-VEGF neutralizing antibodies. Cell numbers were quantified and presented as percentage of αMEM (A) and Ad-CM (B). No significant differences were observed.



Supplementary Figure S3: Ad-CM activates PDGFR signaling-(A)Tumor cells were untreated or treated with Ad-CM at 37°C for 5 min and cell lysates were applied to a Phospho-RTK Array (R&D Systems). Data indicated that Ad-CM stimulation can increase phospho-PDGFR α/β level in E0771 cells (left panel) and increase phospho-cMet level in B16F1 cells (right panel). (B) E0771 cells were untreated or treated with Ad-CM at 37°C for the indicated times. Cell lysates were subject to SDS-PAGE and blotted with the indicated antibodies. Data confirmed Ad-CM-stimulated tyrosine phosphorylation and activation of PDGFR β in E0771.